| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 7, 2013IDE Submission for Symplicity HTN-4 Expands the Indicated Patient Population and Builds upon Medtronic's Rigorous Global Clinical Trial Program for Hypertension Treatment
MINNEAPOLIS - March 7, 2013 - Medtronic, Inc. (NYSE: MDT), announced today that the company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA)...
-
Mar 6, 2013FDA-CMS Parallel Review Program Designed to Enable Efficient and Earlier Patient Access to Innovative Medical Advancements
MINNEAPOLIS - March 6, 2013 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA)and the Centers for Medicare & Medicaid Services (CMS) have accepted the...
-
Dec 17, 2012Published data demonstrate the Symplicity(TM) renal denervation system provides blood pressure reduction in patients with treatment-resistant hypertension sustained to 12 months
MINNEAPOLIS - December 17, 2012 - Medtronic, Inc. (NYSE: MDT) today announced that one-year results from Symplicity HTN-2, the first randomized clinical trial investigating renal denervation, were...
-
Sep 12, 2012Findings Published in The Journal of the American College of Cardiology Suggest Renal Denervation Could Substantially Reduce Cardiovascular Morbidity and Mortality for Patients with a Condition that Affects 120 Million People
MINNEAPOLIS - September 12, 2012 - Medtronic, Inc. (NYSE: MDT) today announced findings from a health-economic analysis published online before print in The Journal of the American College of...
-
Apr 27, 2012Six Month Pooled Outcomes From Randomized and Crossover Patients Following Renal Denervation Presented at the 22nd Annual Scientific Meeting of the European Society of Hypertension Confirm Previous Symplicity Clinical Trial Findings
MINNEAPOLIS & LONDON, Apr 27, 2012 (BUSINESS WIRE) --Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical...
-
Mar 25, 2012Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years
MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Mar. 25, 2012-- Medtronic, Inc. (NYSE:MDT), announced that the Symplicity™ renal denervation system provides safe, significant and sustained blood...
-
Feb 13, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 13, 2012-- Medtronic, Inc. (NYSE: MDT) announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company’s...
-
Nov 4, 2011Presentations Cover Stents and Balloons for Coronary and Peripheral Artery Disease, Transcatheter Valve for Aortic Stenosis, Stent Grafts for Aortic Aneurysms, and Renal Denervation for Treatment-Resistant Hypertension and Heart Failure
MINNEAPOLIS, Nov 04, 2011 (BUSINESS WIRE) -- Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT)...
-
Oct 26, 2011U.S. Clinical Trial of Symplicity(R) Renal Denervation System(TM) Enrolls First Patient
MINNEAPOLIS, Oct 26, 2011 (BUSINESS WIRE) -- Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company's U.S. clinical trial of the Symplicity(R) Renal Denervation...
-
Jul 11, 2011Patient Enrollment in U.S. Clinical Trial of Renal Denervation with Symplicity(R) Catheter System(TM) for Treating Resistant Hypertension to Start Soon
MINNEAPOLIS, Jul 11, 2011 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved the protocol for SYMPLICITY...